All In Biotech

Drug Trial Radar · NCT01649245

Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C

Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial

Last checked: Nov 20, 2026Latest source record: Jan 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

5,000

Planned (sponsor's estimate)

Start

Aug 2012

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
MinaPharm PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 25, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a multi-center study of the efficacy of a new Pegylated Hansenula-derived recombinant interferon α 2a (Reiferon Retard® 160 µg once weekly in combination with ribavirin in treatment of Egyptian patients with chronic hepatitis C for 48 weeks. hepatitis C virus (HCV) viral load will be assessed during therapy at weeks 12, 24 and end of treatment, as well as 24 weeks after therapy is completed.

Conditions

  • Chronic Hepatitis C

Interventions

  • Reiferon retardDrug

    Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained Virologic Response (SVR)Time frame: Assessed 24 weeks after the end of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Liver Institute

    Shebin El-Kom, Monufia Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.